Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Once-daily bronchodilator COPD treatment launched in UK

  • Comment

A new once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease has been launched.

The product, manufactured by GlaxoSmithKline, combines the drug treatment Incruse (umeclidinium) and the Ellipta device.

Umeclidinium 55 mcg is a once-daily long-acting muscarinic antagonist (LAMA), which can relax airway muscles and improve airflow in and out of the lungs.

NICE guidelines recommend offering a LAMA in addition to an inhaled corticosteroid/long-acting beta agonist (ICS/LABA) as “triple therapy” to patients with COPD who remain breathless or have exacerbations despite taking ICS/LABA alone.

GlaxSmithKline said umeclidinium gave clinicians a new LAMA option, which could be of particular help to support the 65% of LAMA patients who used it alongside a combination ICS/LABA treatment.

The launch of Incruse follows marketing authorisation in April 2014. 

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.